An independent Aon study validates DarioHealth's value proposition, demonstrating $5,077 in annual cost savings and improved clinical outcomes for type 2 diabetes patients.
DarioHealth's value proposition is significantly bolstered by an independent Aon analysis demonstrating tangible financial and clinical outcomes for its type 2 diabetes management platform. The study highlights substantial annual cost savings of $5,077 per user and a 23.5% reduction in inpatient discharges, providing empirical evidence to support enterprise adoption and market expansion.
The study found that DarioHealth users with type 2 diabetes experienced 23.5% fewer inpatient discharges compared to matched non-users.
The analysis estimates annual savings ranging from $3.8 million to $10.8 million for a population of 20,000 lives.
DarioHealth Corp. shares gain momentum following an independent Aon study confirming significant clinical and financial outcomes. The analysis reveals that users with type 2 diabetes achieve $5,077 in annual savings and a 23.5% reduction in inpatient discharges compared to non-users.
The study indicates that DarioHealth's platform significantly reduces healthcare costs by $5,077 per user annually and lowers inpatient discharge rates by 23.5% for those with type 2 diabetes.